ImmunityBio (IBRX) Operating Margin (2014 - 2026)
ImmunityBio (IBRX) reported Operating Margin of 157.88% for Q1 2026, up 23220.0% year-over-year from N/an in Q1 2025, and up 6.55% on a QoQ basis from 168.95% in Q4 2025.
ImmunityBio (IBRX) has 13 years of Operating Margin data on file, last reported at 157.88% in Q1 2026.
- Quarterly Operating Margin rose 23220.0% year-over-year to 157.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 185.41% (up 81841.0% YoY) and the FY2025 annual result came in at 226.0%, up 210823.0% from the prior year.
- Operating Margin advanced to 157.88% in Q1 2026 per IBRX's latest filing, from 168.95% in the prior quarter.
- Across five years, Operating Margin topped out at 157.88% in Q1 2026 and bottomed at 685514.29% in Q1 2022.
- The 5-year median for Operating Margin is 30994.44% (2023), against an average of 103232.55%.
- The widest annual swing landed in 2022, when Operating Margin plunged 62345385 bps; it then jumped 65451984 bps in 2023.
- Tracing IBRX's Operating Margin over 5 years: stood at 116301.37% in 2022, then jumped by 47 bps to 61430.94% in 2023, then soared by 99 bps to 918.96% in 2024, then jumped by 82 bps to 168.95% in 2025, then advanced by 7 bps to 157.88% in 2026.
- Per Business Quant, the three latest IBRX Operating Margin figures stand at 157.88% (Q1 2026), 168.95% (Q4 2025), and 173.51% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -157.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.88% |
| Dec 31, 2025 | -168.95% |
| Sep 30, 2025 | -173.51% |
| Jun 30, 2025 | -269.76% |
| Mar 31, 2025 | -390.08% |
| Dec 31, 2024 | -918.96% |
| Sep 30, 2024 | -1,314.33% |
| Jun 30, 2024 | -9,487.39% |
| Mar 31, 2024 | -237,990.00% |
| Dec 31, 2023 | -61,430.94% |
| Sep 30, 2023 | -97,726.83% |
| Jun 30, 2023 | -207,670.73% |
| Mar 31, 2023 | -30,994.44% |
| Dec 31, 2022 | -116,301.37% |
| Sep 30, 2022 | -76,952.54% |
| Jun 30, 2022 | -227,491.43% |
| Mar 31, 2022 | -685,514.29% |
| Dec 31, 2021 | -20,326.67% |
| Sep 30, 2021 | -119,448.48% |
| Jun 30, 2021 | -25,341.00% |
| Mar 31, 2021 | -62,060.43% |
| Dec 31, 2020 | -147,076.19% |
| Sep 30, 2020 | -43,627.15% |
| Jun 30, 2020 | -11,677.98% |
| Mar 31, 2020 | -22,243.64% |
| Dec 31, 2019 | -179,011.11% |
| Sep 30, 2019 | -133,875.00% |
| Jun 30, 2019 | -101,741.18% |
| Mar 31, 2019 | -366,700.00% |
| Dec 31, 2018 | -253,128.57% |
| Sep 30, 2018 | -77,767.74% |
| Jun 30, 2018 | -706,950.00% |
| Mar 31, 2018 | -565,680.00% |
| Dec 31, 2017 | -211,616.67% |
| Sep 30, 2017 | -305,525.00% |
| Jun 30, 2017 | -170,142.86% |
| Mar 31, 2017 | -231,490.91% |
| Dec 31, 2016 | -179,592.86% |
| Sep 30, 2016 | -273,125.00% |
| Jun 30, 2016 | -291,375.00% |
| Mar 31, 2016 | -526,933.33% |
| Dec 31, 2015 | -199,486.67% |
| Sep 30, 2015 | -464,570.00% |
| Jun 30, 2015 | -143,291.21% |
| Mar 31, 2015 | -26,750.83% |
| Dec 31, 2014 | -2,685.71% |
| Sep 30, 2014 | -690.98% |
| Jun 30, 2014 | -966.13% |
| Mar 31, 2014 | -288.81% |